Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin

Kathleen Schmit, Jia-Wei Chen, Sophie Ayama-Canden, Maude Fransolet, Laure Finet, Catherine Demazy, Lionel D’Hondt, Carlos Graux, Carine Michiels

Research output: Contribution to journalArticle

Abstract

TMEM45A is a transmembrane protein involved in tumor progression and cancer resistance to chemotherapeutic agents in hypoxic condition. It is correlated to a low breast cancer patient overall survival. However, little is known about this protein, in particular the mechanisms by which TMEM45A modulates cancer cell chemosensitivity. In this work, the messenger RNA expression of TMEM45A was assessed in head and neck squamous cell carcinoma (HNSCC) and renal cell carcinoma (RCC) biopsies. TMEM45A was upregulated in patients diagnosed for head and neck or renal cancer. Then, the implication of this protein in cisplatin sensitivity was explored in SQD9 and RCC4 + pVHL cells. TMEM45A inactivation decreased cell proliferation and modulated cell responses to cisplatin. Indeed, TMEM45A inactivation increased the sensitivity of SQD9 cells to cisplatin, whereas it rendered RCC4 + pVHL cells resistant to this anticancer agent. Through RNA-sequencing analysis, we identified several deregulated pathways that indicated that the impact on cisplatin sensitivity may be associated to the inhibition of DNA damage repair and to UPR pathway activation. This study demonstrated, for the first time, an anti or a pro-apoptotic role of this protein depending on the cancer type and highlighted the role of TMEM45A in modulating patient responses to treatment.

Original languageEnglish
Article number919
Number of pages18
JournalCell Death and Disease
Volume10
Issue number12
DOIs
Publication statusPublished - 2019

Fingerprint

Cisplatin
Neoplasms
RNA Sequence Analysis
Apoptosis Regulatory Proteins
Proteins
Kidney Neoplasms
Head and Neck Neoplasms
Renal Cell Carcinoma
DNA Repair
Antineoplastic Agents
DNA Damage
Cell Proliferation
Breast Neoplasms
Biopsy
Messenger RNA
Survival
Therapeutics

Cite this

Schmit, Kathleen ; Chen, Jia-Wei ; Ayama-Canden, Sophie ; Fransolet, Maude ; Finet, Laure ; Demazy, Catherine ; D’Hondt, Lionel ; Graux, Carlos ; Michiels, Carine. / Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin. In: Cell Death and Disease. 2019 ; Vol. 10, No. 12.
@article{7fd7af9d5ff34ca6a1ae7d74e50b1448,
title = "Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin",
abstract = "TMEM45A is a transmembrane protein involved in tumor progression and cancer resistance to chemotherapeutic agents in hypoxic condition. It is correlated to a low breast cancer patient overall survival. However, little is known about this protein, in particular the mechanisms by which TMEM45A modulates cancer cell chemosensitivity. In this work, the messenger RNA expression of TMEM45A was assessed in head and neck squamous cell carcinoma (HNSCC) and renal cell carcinoma (RCC) biopsies. TMEM45A was upregulated in patients diagnosed for head and neck or renal cancer. Then, the implication of this protein in cisplatin sensitivity was explored in SQD9 and RCC4 + pVHL cells. TMEM45A inactivation decreased cell proliferation and modulated cell responses to cisplatin. Indeed, TMEM45A inactivation increased the sensitivity of SQD9 cells to cisplatin, whereas it rendered RCC4 + pVHL cells resistant to this anticancer agent. Through RNA-sequencing analysis, we identified several deregulated pathways that indicated that the impact on cisplatin sensitivity may be associated to the inhibition of DNA damage repair and to UPR pathway activation. This study demonstrated, for the first time, an anti or a pro-apoptotic role of this protein depending on the cancer type and highlighted the role of TMEM45A in modulating patient responses to treatment.",
author = "Kathleen Schmit and Jia-Wei Chen and Sophie Ayama-Canden and Maude Fransolet and Laure Finet and Catherine Demazy and Lionel D’Hondt and Carlos Graux and Carine Michiels",
year = "2019",
doi = "10.1038/s41419-019-2088-x",
language = "English",
volume = "10",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "12",

}

Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin. / Schmit, Kathleen; Chen, Jia-Wei; Ayama-Canden, Sophie; Fransolet, Maude; Finet, Laure; Demazy, Catherine; D’Hondt, Lionel; Graux, Carlos; Michiels, Carine.

In: Cell Death and Disease, Vol. 10, No. 12, 919, 2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin

AU - Schmit, Kathleen

AU - Chen, Jia-Wei

AU - Ayama-Canden, Sophie

AU - Fransolet, Maude

AU - Finet, Laure

AU - Demazy, Catherine

AU - D’Hondt, Lionel

AU - Graux, Carlos

AU - Michiels, Carine

PY - 2019

Y1 - 2019

N2 - TMEM45A is a transmembrane protein involved in tumor progression and cancer resistance to chemotherapeutic agents in hypoxic condition. It is correlated to a low breast cancer patient overall survival. However, little is known about this protein, in particular the mechanisms by which TMEM45A modulates cancer cell chemosensitivity. In this work, the messenger RNA expression of TMEM45A was assessed in head and neck squamous cell carcinoma (HNSCC) and renal cell carcinoma (RCC) biopsies. TMEM45A was upregulated in patients diagnosed for head and neck or renal cancer. Then, the implication of this protein in cisplatin sensitivity was explored in SQD9 and RCC4 + pVHL cells. TMEM45A inactivation decreased cell proliferation and modulated cell responses to cisplatin. Indeed, TMEM45A inactivation increased the sensitivity of SQD9 cells to cisplatin, whereas it rendered RCC4 + pVHL cells resistant to this anticancer agent. Through RNA-sequencing analysis, we identified several deregulated pathways that indicated that the impact on cisplatin sensitivity may be associated to the inhibition of DNA damage repair and to UPR pathway activation. This study demonstrated, for the first time, an anti or a pro-apoptotic role of this protein depending on the cancer type and highlighted the role of TMEM45A in modulating patient responses to treatment.

AB - TMEM45A is a transmembrane protein involved in tumor progression and cancer resistance to chemotherapeutic agents in hypoxic condition. It is correlated to a low breast cancer patient overall survival. However, little is known about this protein, in particular the mechanisms by which TMEM45A modulates cancer cell chemosensitivity. In this work, the messenger RNA expression of TMEM45A was assessed in head and neck squamous cell carcinoma (HNSCC) and renal cell carcinoma (RCC) biopsies. TMEM45A was upregulated in patients diagnosed for head and neck or renal cancer. Then, the implication of this protein in cisplatin sensitivity was explored in SQD9 and RCC4 + pVHL cells. TMEM45A inactivation decreased cell proliferation and modulated cell responses to cisplatin. Indeed, TMEM45A inactivation increased the sensitivity of SQD9 cells to cisplatin, whereas it rendered RCC4 + pVHL cells resistant to this anticancer agent. Through RNA-sequencing analysis, we identified several deregulated pathways that indicated that the impact on cisplatin sensitivity may be associated to the inhibition of DNA damage repair and to UPR pathway activation. This study demonstrated, for the first time, an anti or a pro-apoptotic role of this protein depending on the cancer type and highlighted the role of TMEM45A in modulating patient responses to treatment.

UR - http://www.scopus.com/inward/record.url?scp=85075970332&partnerID=8YFLogxK

U2 - 10.1038/s41419-019-2088-x

DO - 10.1038/s41419-019-2088-x

M3 - Article

C2 - 31801939

AN - SCOPUS:85075970332

VL - 10

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 12

M1 - 919

ER -